BioNTech’s $17 Billion War Chest Faces a Pivotal Test as Founders Prepare for Exit

BioNTech faces a pivotal transition with founder exits, declining Covid vaccine sales, and a €17B cash cushion funding high-stakes oncology trials. Q1 results expected to show a loss per share of €1.92.

When BioNTech reports first-quarter results on Tuesday, the numbers will tell only half the story. The Mainz-based biotech is navigating one of the most consequential transitions in its history — a founder departure, a shrinking Covid franchise, and an ambitious oncology pipeline that must deliver before the cash cushion starts to thin.

The headline figures are expected to be grim. Analysts forecast a normalized loss per share of €1.92, reflecting the ongoing revenue decline from Covid-19 vaccines. In the last reported quarter, sales slumped 13.5% to $1.065 billion, while the per-share loss of $0.39 missed the consensus estimate of $0.30. For the full year, management projects total revenue of up to €2.3 billion — a far cry from the pandemic-era peaks.

A $17 Billion Cushion and a Founder Exodus

The financial picture is softened by a formidable war chest: BioNTech ended 2025 with approximately €17.2 billion in cash and equivalents. That buffer allows the company to sustain research spending that will likely exceed €2.2 billion this year as it pours resources into its oncology pipeline.

But the human capital story is equally dramatic. In March, founders Ugur Sahin and Özlem Türeci announced plans to step back from day-to-day operations by the end of 2026 to build a new mRNA venture. The news sent shares into a tailspin from which they have only partially recovered. Tuesday’s earnings call will be the first chance for investors to hear directly from the management team since that bombshell.

Pipeline Momentum Meets Clinical Setbacks

The oncology pipeline remains the primary source of investor conviction — and the biggest variable. Seven major late-stage data readouts are expected over the course of 2026, with 15 Phase 3 studies planned by year-end.

The most compelling near-term catalyst is Pumitamig. In a Phase 2 lung cancer trial, the drug delivered an 82% response rate when combined with chemotherapy, with median overall survival reaching nearly 17 months. Those results have buoyed analyst confidence. H.C. Wainwright reiterated its buy rating in late April with a $130 price target, while Jefferies sees fair value at $138. The consensus among 18 analysts stands at “Moderate Buy” with an average target of $133.07 — a roughly 29% premium to the current share price of around $103.

Yet the Covid business continues to throw up obstacles. Pfizer and BioNTech recently halted enrollment in a large US study of their updated Covid vaccine due to insufficient participant numbers, dimming hopes for near-term data and future commercial potential from that program.

The Valuation Gap

The stock entered trading at roughly $97 after the long weekend, reflecting the market’s uncertainty about the transition. The wide dispersion in analyst targets — ranging up to $171 — underscores just how binary the outcome remains. A successful oncology pivot could unlock enormous value; failure to deliver would leave a company with declining revenues and no clear growth engine.

Tuesday’s earnings will provide concrete updates on patient enrollment in ongoing Phase 3 trials. That data point, more than the quarterly loss itself, will determine whether the stock can close the gap to its consensus target — or whether the founder exit marks the beginning of a longer, more painful transformation.